Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pioglitazone for metabolic dysfunction-associated fatty liver disease
PACTR202502652902049Phase 4Unknown
- Sponsor
- my self
- Start
- Jun 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4 trial of pioglitazone in metabolic dysfunction-associated steatotic liver disease (MASLD) (2 arms), sponsored by my self. Primary endpoint: Improvement of MAFLD by FibroScan. Status: unknown.
02
Drugs
pioglitazone
03
Conditions
metabolic dysfunction-associated steatotic liver disease (MASLD)
Beyond the preview
Go deeper on PACTR202502652902049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202502652902049.